In a Chinese trial published in JAMA oncology, the addition of adjuvant #capecitabine improved failure-free survival (FFS) among patients with locoregionally advanced #nasopharyngeal_carcinoma (LA-NPC) who received concurrent chemoradiotherapy. In this phase III randomized trial, 180 eligible patients were randomly assigned 1:1 to receive either capecitabine (1000 mg/m2 twice daily for 14 days every 3 weeks for 8 cycles) or observation following CCRT (100 mg/m2 cisplatin every 3 weeks for 2 to 3 cycles). Failure-free survival was improved with adjuvant capecitabine (3 years FFS 83.3% vs 72.2%; 5 years FFS 78.5% vs 65.9%; HR= 0.53; P = .03)."